REG - Oxford Biomedica PLC - 2023 Annual Report and Accounts

Oxford BioMedicaAnnouncement

30/04/2024 17:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240430:nRSd6764Ma&default-theme=true

RNS Number : 6764M  Oxford Biomedica PLC  30 April 2024

Oxford Biomedica

2023 Annual Report and Accounts

 

Oxford, UK - 30 April 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica" or "the Company"), a quality and innovation-led cell and gene
therapy CDMO, gives notice that the 2023 Annual report and accounts is now
available on the "Investors" section of the Group's website at www.oxb.com
(http://www.oxb.com) . In accordance with Listing rule 9.6.1, the 2023 Annual
report and accounts has also  been submitted to the Financial Conduct
Authority for publication through the National Storage Mechanism and will
shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

Further copies of the 2023 Annual report and accounts are available from the
Company Secretary, Oxford Biomedica plc, Windrush Court, Transport Way,
Oxford, OX4 6LT, United Kingdom (telephone number: +44 (0) 1865 783 000). The
Company confirms that, in compliance with DTR 6.3.5(1A), the regulated
information required under DTR 6.3.5, is available in unedited full text
within the Annual Report available on the National Storage Mechanism and in
compliance with DTR 6.3.5(3) is available on the Company's website as noted
above.

 

-Ends-

 

 For further information, please contact:

 Oxford Biomedica plc:                     Tel: +44 (0)1865 783 000

 Natalie Walter, Company Secretary

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene
therapy CDMO with a mission to enable its clients to deliver life changing
therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, the Company has more
than 25 years of experience in viral vectors; the driving force behind the
majority of gene therapies. The Company collaborates with some of the world's
most innovative pharmaceutical and biotechnology companies, providing viral
vector development and manufacturing expertise in lentivirus, adeno-associated
virus (AAV), adenoviral vectors, and other viral vector types. Oxford
Biomedica's world-class capabilities span from early-stage development to
commercialisation. These capabilities are supported by robust
quality-assurance systems, analytical methods and depth of regulatory
expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It
has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon
and Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com
(https://www.oxb.com/) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica/) and YouTube
(https://www.youtube.com/user/OxfordBioMedica) .

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSURSVRSVUSOAR